ArticleScientific reports2025
Nomogram for thromboembolic events in primary membranous nephropathy associated with PLA2R antibody.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with nephrotic syndrome, particularly those with primary membranous nephropathy (pMN), are at a heightened risk of thromboembolic events. The presence of phospholipase A2 receptor (PLA2R) antibody serves as an indicator of active primary membranous nephropathy. Identifying high-risk patients for thromboembolic events is crucial for facilitating effective communication between healthcare providers and patients, evaluating treatment outcomes, and assessing medical costs. This study aimed to develop a practical model for predicting the probability of thromboembolic events in patients with PLA2R-related primary membranous nephropathy. A total of 1384 patients diagnosed with PLA2R antibody-related primary membranous nephropathy were included in this study. The model group included 969 patients enrolled before August 2020, while the external validation group consisted of 415 patients enrolled later. Patients in the modeling group were divided into the thromboembolic and non-thromboembolic subgroups. Logistic regression analysis was performed, and a nomogram was established based on the results. The predictive performance of the nomogram was evaluated by the area under the receiver operating characteristic curve (AUC), calibration curves, and decision curve analysis (DCAs). The modeling group comprised 126 (13.0%) patients with thromboembolism, and significant differences were observed between the thromboembolism and non-thromboembolism subgroups. The risk factors included in the nomogram included age, Anti-PLA2R antibody, and 24-hour urine protein quantification. The AUC value of the nomogram was 0.741 (95% CI 0.695-0.788, P < 0.001). In addition, the calibration curves demonstrated acceptable agreement between the predicted outcomes by the nomogram and the actual values. DCA curves showed good positive net benefits in the predictive model. The external validation also confirmed the reliability of the prediction nomogram. This predictive nomogram including Anti-PLA2R antibody, age, and 24-hour urine protein quantification may facilitate the prediction of the thromboembolic risk in patients with PLA2R-related pMN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.